Tarsus Pharmaceuticals

NasdaqGS:TARS Stock Report

Mkt Cap: US$453.2m

Tarsus Pharmaceuticals Financial Health

How is Tarsus Pharmaceuticals's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: TARS's short term assets ($250.3M) exceed its short term liabilities ($11.7M).

Long Term Liabilities: TARS's short term assets ($250.3M) exceed its long term liabilities ($19.6M).


Debt to Equity History and Analysis

Debt Level: TARS has more cash than its total debt.

Reducing Debt: Insufficient data to determine if TARS's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TARS has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: TARS has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 16.9% each year


Discover healthy companies